# A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Source: https://onco.cc/trials/nct07287995/  
OnCo record `nct07287995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early study of ASP2998, an experimental antibody drug carrying a cancer-killing payload and an immune activator. It is recruiting people with advanced solid tumors for treatment alone or with tumor-specific standard therapies.

## Summary

NCT07287995 evaluates the TROP2-directed dual-payload ADC ASP2998 alone and in tumor-specific combinations with pembrolizumab, enfortumab vedotin or carboplatin. ASP2998 carries a TOP1 inhibitor and a STING agonist. The registry last posted 2 September 2026 lists recruiting status, actual start on 5 February 2026, estimated enrollment of 428 and estimated primary completion on 30 June 2029. The earlier ASCO 2026 trial-in-progress abstract planned 196 participants; neither figure is a treated-patient count. No results are posted. The trial includes urothelial, non-small-cell lung, gastric/gastroesophageal junction and HER2-negative breast cancer cohorts. Prior TROP2, STING or TOP1 therapy permissions differ by cohort; the current protocol, rather than the older trial-in-progress abstract, determines eligibility. This is advanced disease research, not established adjuvant treatment.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07287995
- Phase: 1/2
- Setting: A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 428

## Sources

- ClinicalTrials.gov NCT07287995: https://clinicaltrials.gov/study/NCT07287995
- Astellas study 2998-CL-0101: https://www.clinicaltrials.astellas.com/study/2998-CL-0101
- Astellas: TOP1 inhibitor and STING agonist payloads: https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_pre_en.pdf
- ASCO 2026 trial-in-progress abstract TPS2665: https://doi.org/10.1200/jco.2026.44.16_suppl.tps2665

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [ASP2998](https://onco.cc/drugs/asp2998/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct07287995.json